Related Experiment Video
Updated: Jul 14, 2026
09:29
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
Neuromyelitis optica: new findings on pathogenesis
1Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA.
International Review of Neurobiology
|May 29, 2007
Summary
Neuromyelitis optica (NMO) is a distinct CNS demyelinating disease. Research suggests NMO is driven by humoral mechanisms, with NMO-IgG targeting aquaporin-4 potentially playing a key pathogenic role.
Area of Science:
- Neuroimmunology
- Demyelinating Diseases
Background:
- Neuromyelitis optica (NMO) is a rare CNS demyelinating disorder affecting the optic nerve and spinal cord.
- Evidence suggests NMO is distinct from multiple sclerosis (MS), with humoral mechanisms dominating its pathogenesis.
Observation:
- NMO frequently coexists with systemic autoimmune diseases.
- Plasmapheresis can be an effective therapy for severe NMO attacks.
- Immunopathology reveals complement activation and immunoglobulin deposition in NMO.
Findings:
- The serum autoantibody NMO-IgG, targeting aquaporin-4 (AQP4), is a potential biomarker for NMO.
- NMO-IgG is found in most patients with NMO-spectrum disorders (NMOSD).
- NMO-IgG can modulate AQP4 function and activate complement, suggesting pathogenicity.
Implications:
- NMO and NMOSD represent a distinct disease entity from classical MS.
- NMO-IgG is a crucial diagnostic and potentially therapeutic target.
- Understanding NMO immunopathogenesis advances treatment strategies for these rare neurological disorders.
Related Concept Videos
01:26Encephalitis ll: Pathophysiology
Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
01:26Bacterial Meningitis II: Pathophysiology
Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...